Author:
Huynh Aimee,Gray Paul E,Sullivan Anna,Mackie Joseph,Guerin Antoine,Rao Geetha,Pathmanandavel Karrnan,Mina Erika Della,Hollway Georgina,Hobbs Matthew,Enthoven Karen,O’Young Patrick,McManus Sam,Wainwright Luke H.,Higgins Megan,Noon Fallon,Wong Melanie,Bastard Paul,Zhang Qian,Casanova Jean-Laurent,Hsiao Kuang-Chih,Pinzon-Charry Alberto,Ma Cindy S,Tangye Stuart G.
Abstract
AbstractAdvanced genomic technologies such as whole exome or whole genome sequencing have improved diagnoses and disease outcomes for individuals with genetic diseases. Yet, variants of unknown significance (VUS) require rigorous validation to establish disease causality or modification, or to exclude them from further analysis. Here, we describe a young individual of Polynesian ancestry who in the first 13 mo of life presented with SARS-CoV-2 pneumonia, severe enterovirus meningitis and adenovirus gastroenteritis, and severe adverse reaction to MMR vaccination. Genomic analysis identified a previously reported pathogenic homozygous variant in IFNAR1 (c.1156G > T, p.Glu386* LOF), which is common in Western Polynesia. Moreover, a new and putatively deleterious canonical splice site variant in DOCK8 was also found in homozygosity (c.3234 + 2T > C). This DOCK8 variant is common in Polynesians and other under-represented ancestries in large genomic databases. Despite in silico bioinformatic predictions, extensive in vitro and ex vivo analysis revealed the DOCK8 variant likely be neutral. Thus, our study reports a novel case of IFNAR1 deficiency, but also highlights the importance of functional validation of VUS, including those predicted to be deleterious, and the pressing need to expand our knowledge of the genomic architecture and landscape of under-represented populations and ancestries.
Funder
University of New South Wales
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Hernandez N, Bucciol G, Moens L, Le Pen J, Shahrooei M, Goudouris E, et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med. 2019;216(9):2057–70.
2. Gothe F, Hatton CF, Truong L, Klimova Z, Kanderova V, Fejtkova M, et al. A novel case of homozygous Interferon Alpha/Beta receptor alpha chain (IFNAR1) Deficiency with Hemophagocytic Lymphohistiocytosis. Clin Infect Dis. 2022;74(1):136–9.
3. Meyts I, Casanova JL. Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway. Eur J Immunol. 2021;51(5):1039–61.
4. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515).
5. Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med. 2022;219(8).